Embecta Corp. (NASDAQ:EMBC) Shares Purchased by Algert Global LLC

Algert Global LLC boosted its position in Embecta Corp. (NASDAQ:EMBC - Free Report) by 45.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 152,301 shares of the company's stock after purchasing an additional 47,260 shares during the period. Algert Global LLC owned about 0.26% of Embecta worth $3,145,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC grew its holdings in Embecta by 175.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,216 shares of the company's stock worth $25,000 after acquiring an additional 774 shares during the period. Sterling Capital Management LLC boosted its position in shares of Embecta by 796.3% during the 4th quarter. Sterling Capital Management LLC now owns 1,685 shares of the company's stock worth $35,000 after purchasing an additional 1,497 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Embecta by 111.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,284 shares of the company's stock worth $150,000 after purchasing an additional 3,835 shares during the period. Oppenheimer Asset Management Inc. purchased a new position in shares of Embecta in the 4th quarter valued at about $209,000. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Embecta in the 4th quarter valued at about $215,000. Hedge funds and other institutional investors own 93.83% of the company's stock.

Analyst Ratings Changes

Separately, Mizuho began coverage on shares of Embecta in a report on Thursday, April 10th. They issued a "neutral" rating and a $15.00 target price for the company.

Insider Transactions at Embecta

In related news, Director Milton Mayo Morris sold 3,100 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $16.38, for a total transaction of $50,778.00. Following the completion of the sale, the director now owns 36,133 shares of the company's stock, valued at approximately $591,858.54. This represents a 7.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.42% of the company's stock.

Embecta Trading Up 1.5%

Shares of NASDAQ:EMBC traded up $0.19 on Tuesday, hitting $12.60. The company had a trading volume of 115,252 shares, compared to its average volume of 448,261. The company has a market cap of $732.49 million, a PE ratio of 12.60, a PEG ratio of 0.78 and a beta of 1.24. Embecta Corp. has a 52-week low of $10.83 and a 52-week high of $21.48. The business has a 50 day moving average of $12.44 and a 200 day moving average of $15.75.

Embecta (NASDAQ:EMBC - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.66 by $0.04. The company had revenue of $259.00 million for the quarter, compared to analyst estimates of $261.77 million. Embecta had a negative return on equity of 19.22% and a net margin of 5.25%. The business's revenue for the quarter was down 9.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.67 EPS. As a group, equities analysts predict that Embecta Corp. will post 2.85 EPS for the current year.

Embecta Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Wednesday, May 28th will be paid a dividend of $0.15 per share. The ex-dividend date of this dividend is Wednesday, May 28th. This represents a $0.60 annualized dividend and a yield of 4.76%. Embecta's dividend payout ratio is presently 66.67%.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.